Home › Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration
 

Keywords :   


Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration

2016-04-15 03:46:09| drugdiscoveryonline Home Page

Transplant Genomics Inc. ("TGI") and Quark Pharmaceuticals, Inc. ("Quark") today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI's TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with Quark's proprietary drug candidate QPI-1002.

Tags: development collaboration discovery announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »